Thymosin Alpha-1 5mg
28-residue acetylated thymic peptide studied in immune-modulation research.
28-residue acetylated thymic peptide studied in immune-modulation research.
The primary literature on this compound includes Goldstein et al., Ann NY Acad Sci (2007). The references below link directly to the published record.
Every lot is synthesized in the USA, verified by HPLC, and ships with its Certificate of Analysis. It is supplied strictly for laboratory research use.
Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.
Published research
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialLiu D, et al. BMJ. 2025.PubMed →
- Safety and efficacy of Thymosin alpha-1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trialShen Y, et al. Hepatol Int. 2022.PubMed →
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialWu J, et al. Crit Care. 2013.PubMed →
- Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control studyWang X, et al. Inflammation. 2011.PubMed →
- The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialIino S, et al. J Viral Hepat. 2005.PubMed →
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialAndreone P, et al. Liver. 1996.PubMed →